Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)

AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid therapeutic expansion as new systemic and topical agents reshape physician decision-making and competitive dynamics. Since the launch of Dupixent in 2017, the U.S. AD market has expanded to include multiple IL-13 inhibitors (Adbry, Ebglyss), an IL-31 inhibitor (Nemluvio), systemic JAK inhibitors (Rinvoq, Cibinqo), and newer topical options such as Vtama. As biologics and JAK inhibitors increasingly compete for earlierline use, dermatologists must weigh their differences in efficacy, safety, onset of action, dosing frequency, and payer requirements. This report explores evolving prescribing patterns, key drivers of treatment selection, and emerging opportunities in a rapidly shifting market landscape.

Questions answered

• Which product attributes do U.S. dermatologists perceive as most important when treating their moderate to severe AD patients?
• What patient share do key biologics (e.g., Dupixent, Adbry, Ebglyss, Nemluvio) and JAK inhibitors (e.g., Rinvoq, Cibinqo) garner among moderate and severe AD patients?
• Which therapies are dominant in the first, second, and third lines? What are the drivers and obstacles to using key brands, and what are the reasons for their discontinuation?
• What are the recent and anticipated changes in moderate to severe AD treatment practices?

Geography: United States

Primary research: Survey of 70 U.S. dermatologists and 30 U.S. pediatricians

Key drugs covered: Adbry (tralokinumab), Cibinqo (abrocitinib), Dupixent (dupilumab), Ebglyss (lebrikizumab), Nemluvio (nemolizumab), Rinvoq (upadacitinib), Vtama (tapinarof)

Key analyses

• Factors influencing disease management and treatment decisions
• Drivers and constraints of treatment selection
• Physician-reported treatment practices and brand-level patient shares
• Rationale for changes in treatment approach
• Physician insight on persistency and compliance
• Physician-reported recent / anticipated changes in brand usage or treatment approach

Product description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
• Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.